Transport
East Cooper Community Hospital, INC.
East Cooper Community Hospital, INC. was paid $3.05M by Medicaid between Jan 2018 and Jan 2024, across 86 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 22% of everything it billed.
33Billing provider infoEAST COOPER COMMUNITY HOSPITAL, INC.
MT PLEASANT, SC 29464
MT PLEASANT, SC 29464
33aNPI1821026816assigned 06/29/2006
33bProvider typeAmbulance
28Total paid$3.05M
24GClaims80,927
24DCodes billed86
24AFirst – last monthJan 2018 – Jan 2024
Compared with peers
Next to other Ambulance providers in South Carolina
Rank by total paid#6 of 51
Median peer was paid$630K
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,810 | $448K | |
| 2019 | 11,896 | $442K | |
| 2020 | 9,523 | $308K | |
| 2021 | 14,532 | $627K | |
| 2022 | 14,942 | $589K | |
| 2023 | 13,073 | $594K | |
| 2024incomplete | 1,151 | $40K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 22% | 4,726 | 3,907 | $682K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 10% | 726 | 690 | $316K |
| 81025 | 6.9% | 1,855 | 1,781 | $212K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 4,842 | 4,428 | $211K |
| 80048 | Basic metabolic panel (calcium, ionized) | 5.4% | 1,759 | 1,507 | $165K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.9% | 725 | 682 | $150K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 1,929 | 547 | $138K |
| 36415 | Collection of venous blood by venipuncture | 3.5% | 41 | 36 | $108K |
| 81001 | 3.5% | 2,310 | 2,113 | $107K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 810 | 750 | $105K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 4,218 | 3,578 | $92K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.9% | 1,512 | 518 | $87K |
74 more codes
| 81003 | 2.6% | 1,414 | $80K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 896 | $72K |
| J3490 | Unclassified drugs | 1.9% | 806 | $58K |
| J2704 | Injection, propofol, 10 mg | 1.7% | 1,528 | $53K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 1.3% | 346 | $41K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 1.3% | 939 | $41K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 2,070 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 1,228 | $38K |
| 87081 | 1.1% | 1,222 | $33K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 985 | $28K |
| 99285 | Emergency room visit (most serious) | <1% | 1,901 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,042 | $18K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 311 | $15K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,008 | $15K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,173 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,165 | $14K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 174 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,064 | $13K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 82 | $11K |
| 82962 | <1% | 368 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,902 | $8K |
| A9150 | Non-prescription drugs | <1% | 127 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,373 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 75 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,558 | $3K |
| 87430 | <1% | 377 | $3K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 112 | $2K |
| 87070 | <1% | 26 | $2K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 169 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 158 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,506 | $2K |
| 84703 | <1% | 726 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 65 | $1K |
| 84484 | <1% | 1,132 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 19 | $869.58 |
| 84702 | <1% | 65 | $741.35 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,900 | $675.47 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $606.33 |
| 85610 | <1% | 626 | $305.44 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 201 | $266.43 |
| 97161 | <1% | 12 | $262.72 | |
| 86850 | <1% | 58 | $216.80 | |
| 83690 | <1% | 1,405 | $215.17 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 116 | $102.60 |
| 83735 | <1% | 1,115 | $66.61 | |
| 87077 | <1% | 60 | $43.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,204 | $40.08 |
| 83880 | <1% | 13 | $33.89 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,681 | $30.69 |
| 86900 | <1% | 509 | $27.47 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,756 | $24.11 |
| 86901 | <1% | 509 | $19.80 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,989 | $13.83 |
| 85730 | <1% | 442 | $10.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 91 | $9.68 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 64 | $6.83 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,485 | $2.14 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 26 | $0.00 |
| 87186 | 0% | 256 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 24 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 35 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 16 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 346 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 990 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 21 | $0.00 |
| A9270 | Non-covered item or service | 0% | 88 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 12 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 50 | $0.00 |
| 96376 | 0% | 74 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 24 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 112 | $0.00 |
| 86592 | 0% | 12 | $0.00 | |
| 85027 | 0% | 13 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJORDAN, HEATH (CFO)